HK1203852A1 - 具有激酶抑制活性的二苯基甲醇-吡唑衍生物及其用途 - Google Patents

具有激酶抑制活性的二苯基甲醇-吡唑衍生物及其用途

Info

Publication number
HK1203852A1
HK1203852A1 HK15104751.4A HK15104751A HK1203852A1 HK 1203852 A1 HK1203852 A1 HK 1203852A1 HK 15104751 A HK15104751 A HK 15104751A HK 1203852 A1 HK1203852 A1 HK 1203852A1
Authority
HK
Hong Kong
Prior art keywords
benzhydrol
inhibitory activity
pyrazole derivatives
kinase inhibitory
kinase
Prior art date
Application number
HK15104751.4A
Other languages
English (en)
Inventor
‧基夫
‧瓦納
‧克拉克
‧張
‧吉昆朱
‧庫奧佐
‧湯姆森
Original Assignee
X Rx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by X Rx Inc filed Critical X Rx Inc
Publication of HK1203852A1 publication Critical patent/HK1203852A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Transplantation (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
HK15104751.4A 2012-01-09 2015-05-19 具有激酶抑制活性的二苯基甲醇-吡唑衍生物及其用途 HK1203852A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261584569P 2012-01-09 2012-01-09
PCT/US2013/020834 WO2013106432A1 (en) 2012-01-09 2013-01-09 Benzhydrol-pyrazole derivatives having kinase inhibitory activity and uses thereof

Publications (1)

Publication Number Publication Date
HK1203852A1 true HK1203852A1 (zh) 2015-11-06

Family

ID=48781860

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15104751.4A HK1203852A1 (zh) 2012-01-09 2015-05-19 具有激酶抑制活性的二苯基甲醇-吡唑衍生物及其用途

Country Status (8)

Country Link
US (1) US9394256B2 (zh)
EP (1) EP2802324A4 (zh)
JP (4) JP6131272B2 (zh)
CN (1) CN104302289A (zh)
AU (3) AU2013208104B2 (zh)
CA (1) CA2862832A1 (zh)
HK (1) HK1203852A1 (zh)
WO (1) WO2013106432A1 (zh)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9394256B2 (en) * 2012-01-09 2016-07-19 X-Chem, Inc. Benzhydrol-pyrazole derivatives having kinase inhibitory activity and uses thereof
US11104668B2 (en) 2013-12-13 2021-08-31 Hoffmann-La Roche Inc. Inhibitors of bruton's tyrosine kinase
EP3288384A4 (en) * 2015-05-01 2019-01-23 Georgia State University Research Foundation BENZHYDROL DERIVATIVES FOR ADMINISTERING CONDITIONS RELATED TO HYPOXIC INDUCIBLE FACTORS
WO2017157873A1 (en) 2016-03-17 2017-09-21 F. Hoffmann-La Roche Ag 5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar
CN111662270A (zh) * 2019-03-05 2020-09-15 中国医学科学院药物研究所 碘同位素标记苄苯醚衍生物、及其制法和药物组合物与用途
MX2021015996A (es) 2019-07-11 2022-06-08 Escape Bio Inc Indazoles y azaindazoles como inhibidores de cinasa de repetición rica en leucina 2 (lrrk2).
CN112920245B (zh) * 2019-12-05 2023-11-07 成都先导药物开发股份有限公司 一种合成On-DNA二氢吡唑化合物的方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19629828A1 (de) * 1996-07-24 1998-01-29 Bayer Ag Carbanilide
EP1651612B9 (en) * 2003-07-22 2012-09-05 Astex Therapeutics Limited 3,4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
US20090221599A1 (en) * 2006-03-20 2009-09-03 Edward Boyd Phthalazinone pyrazole derivatives, their manufacture and use as pharmaceutical agents
JP2009530342A (ja) * 2006-03-20 2009-08-27 エフ．ホフマン−ラ ロシュ アーゲー Ｂｔｋおよびｓｙｋ蛋白キナーゼを阻害する方法
JP5587193B2 (ja) * 2007-10-23 2014-09-10 エフ．ホフマン−ラ ロシュ アーゲー 新規なキナーゼ阻害剤
FR2947546B1 (fr) * 2009-07-03 2011-07-01 Sanofi Aventis Derives de pyrazoles, leur preparation et leur application en therapeutique
US9394256B2 (en) * 2012-01-09 2016-07-19 X-Chem, Inc. Benzhydrol-pyrazole derivatives having kinase inhibitory activity and uses thereof

Also Published As

Publication number Publication date
AU2013208104A8 (en) 2014-09-11
EP2802324A4 (en) 2015-07-15
CN104302289A (zh) 2015-01-21
CA2862832A1 (en) 2013-07-18
WO2013106432A1 (en) 2013-07-18
JP6131272B2 (ja) 2017-05-17
AU2018201295B2 (en) 2019-11-28
EP2802324A1 (en) 2014-11-19
JP2019048813A (ja) 2019-03-28
AU2018201295A1 (en) 2018-03-15
AU2020201447A1 (en) 2020-03-19
JP2017149755A (ja) 2017-08-31
AU2013208104B2 (en) 2017-11-23
US9394256B2 (en) 2016-07-19
JP2020189852A (ja) 2020-11-26
AU2013208104A1 (en) 2014-07-24
JP2015506362A (ja) 2015-03-02
US20150005345A1 (en) 2015-01-01

Similar Documents

Publication Publication Date Title
HK1215577A1 (zh) 蛋白激酶抑制劑
HK1216147A1 (zh) 取代的苯甲酰基 -氟- -亞氨基- -甲基- -二氫嘧啶- -酮衍生物
HK1203852A1 (zh) 具有激酶抑制活性的二苯基甲醇-吡唑衍生物及其用途
EP2828258A4 (en) NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND THEIR USE
PT2955185T (pt) Inibidores da atividade de cinase de pirazole substituído policíclico e sua utilização
EP2833889A4 (en) PROTEIN KINASE C HEMMER AND USES THEREOF
HK1208678A1 (zh) -二氨基吡唑激酶抑制劑
HK1209277A1 (zh) -三嗪- -甲酰胺激酶抑制劑
HK1209726A1 (zh) 蛋白激酶抑制劑
HK1205506A1 (zh) 炔類化合物的蛋白激酶抑制劑
EP2834246A4 (en) COMBINED PRODUCTS COMPRISING TYROSINE KINASE INHIBITORS AND THEIR USE
HK1208460A1 (zh) 蛋白激酶抑制劑
EP2879679A4 (en) ANTIBACTERIAL PROTEIN KINASE INHIBITORS
HK1198833A1 (zh) -酰基肽衍生物及其應用
SG11201504142WA (en) Inhibitory oligonucleotide and use thereof
HK1210036A1 (zh) 作為蛋白激酶抑制劑的氨基異喹啉衍生物
EP2876107A4 (en) ISOCHINOLINE-5-CARBOXAMIDE DERIVATIVITY WITH PROTEIN CHINESE-DAMAGING EFFECT
EP2754659A4 (en) 4-SUBSTITUTED- (3-SUBSTITUTED-1H-PYRAZOLE-5-AMINO) -PYRIMIDINES DERIVATIVES HAVING PROTEIN KINASE INHIBITION ACTIVITY AND USE THEREOF
SI2882715T1 (sl) Derivati pirazola in njihova uporaba kot antagonisti LPAR5
HK1203848A1 (zh) 具有激酶抑制活性的 衍生物及其用途
GB201219296D0 (en) Pyrazole derivatives
GB201219289D0 (en) Pyrazole derivatives
GB201218245D0 (en) Pyrazole derivatives
SG10201706707VA (en) Inhibitory oligonucleotide and use thereof
GB201209458D0 (en) Novel compounds and their use as kinase inhibitors